SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

A reported take-private bid from Irth Capital, joined by Papa Johns largest U.S. franchisee, is driving takeover speculation; traders are divided between expecting a deal and doubting it will close. Frustration over the boards handling of prior offers is amplified by weak sales, a reduced outlook and the suspended dividend.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

CCJs slide to a 52-week low, with earnings approaching, is driving attention as traders debate whether put-selling points to support or whether uranium-sector weakness and concerns about Cigar Lake operations leave room for further declines. Some see the selloff as a buying opportunity, while others expect continued pressure.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Attention centers on Aurinias ongoing patent litigation with generic drugmakers and anticipated court updates; some traders speculate that delays could precede settlements, while others are frustrated by the lack of confirmed news and weak trading. Lupkynis sales growth and an analyst upgrade support the bullish case, with investors also watching for the upcoming quarterly results.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIB is drawing attention for choppy, range-bound trading, with traders watching technical support and resistance for signs of a breakout. The community is split between dip-buying and hopes for a meme-coin rally, and frustration over stagnation, limited utility, and repeated reversals.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention amid concern that rising oil, inflation and uncertainty around Fed policy could keep pressure on small caps, which are sensitive to borrowing costs and economic conditions. Traders are split between downside risks and heavy bearish positioning, and hopes for a small-cap rotation or oversold bounce as yields ease and technology stocks weaken.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is drawing attention after a quarterly earnings beat and record funded backlog, with traders also pointing to LOCUST laser orders as evidence of demand for counter-drone systems. The reaction is broadly bullish, though some caution that converting backlog into revenue and cash flow remains the key test.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is drawing attention as Treasury yields retreat and investors rotate toward long-duration bonds amid equity weakness and concerns about AI-related credit risks. Traders debate whether the bond rally reflects safe-haven demand and recession fears or expectations for easing inflation and Fed policy, while persistent inflation and possible rate hikes remain risks.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention amid volatile natural-gas futures and concern about continued weakness, with traders pointing to mild-weather forecasts, ample supply and storage builds as bearish pressures. Bulls are looking for a winter-weather or storage-driven rebound, while others warn that BOILs daily leverage and futures-roll decay make it risky to hold through the swings.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solars sharp selloff and repeated 52-week-low tests dominate discussion, with traders citing higher yields, uncertainty around solar incentives and limited visibility into future bookings as pressures. Some see the decline as an oversold buying opportunity based on the companys backlog and domestic-manufacturing position, while others expect further weakness.

TOSHI

TOSHI is drawing attention as holders watch for a technical breakout after repeated tests of resistance, citing rising volume and possible short covering while adding to positions. The bullish calls and squeeze speculation are tempered by concerns about weak price action, failed breakouts and broader crypto-market weakness; no confirmed new catalyst is evident.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

Equity

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Lighthouse Point, FL.

ZyVersa Therapeutics Inc

Neutral Sentiment

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.001
Prev Close	$0.001
Open	$0.001
Dividend Yield	0.00%
50-Day Moving Average	$0.0834
Beta	-12.25
Avg. Volume	3,403.29
PE Ratio	0.00

52-Week High	$0.30
52-Week Low	$0.0002
Market Capitalization	$8,096.00
EPS (Annual)	-$4.18
Price to Book	-0.00
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZVSA Fundamentals